XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement

XTL Biopharmaceuticals Sponsored ADR ( (XTLB) ) has shared an announcement.

On January 13, 2026, XTL Biopharmaceuticals Ltd. signed a binding letter of intent with Beyond Air, Inc. to acquire all of Beyond Air’s approximately 85% stake in NeuroNOS Ltd., an Israeli private biopharmaceutical company developing small‑molecule therapies for autism spectrum disorder and other neurological conditions by regulating nitric oxide levels in the brain. Under the proposed terms, XTL would pay Beyond Air with newly issued American Depositary Shares sufficient to give it 19.99% ownership of XTL, three‑year warrants to maintain that stake, a US$1 million cash payment within 60 days of closing, and up to US$5.5 million in clinical and regulatory milestones, plus additional commercial milestone payments tied to future NeuroNOS product sales, while offering minority NeuroNOS shareholders a post‑closing share‑exchange option into XTL. The letter of intent also restricts Beyond Air’s ability to sell XTL ADSs until FDA approval of XTL’s first autism drug candidate, and XTL’s board and audit committee approved on January 12, 2026, a concurrent private placement of up to US$2 million at a 20% discount to support the upfront payment and transaction costs, subject to shareholder, regulatory and stock‑exchange approvals. The deal, which remains contingent on due diligence, definitive agreements and multiple approvals, is positioned as a strategic move to expand XTL’s growth‑oriented asset base and deepen its presence in neurodevelopmental and neurodegenerative therapeutics, potentially altering its portfolio mix and shareholder base if completed.

Spark’s Take on XTLB Stock

According to Spark, TipRanks’ AI Analyst, XTLB is a Underperform.

XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.

To see Spark’s full report on XTLB stock, click here.

More about XTL Biopharmaceuticals Sponsored ADR

XTL Biopharmaceuticals Ltd. is an intellectual property portfolio company that owns 100% of The Social Proxy Ltd., a web data firm, and has sublicensed an IP portfolio related to hCDR1 for the treatment of lupus (SLE). The company’s securities trade on both the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the ticker XTLB, reflecting its dual listing and exposure to U.S. and Israeli investors.

Average Trading Volume: 76,516

Technical Sentiment Signal: Sell

Current Market Cap: $6.63M

For an in-depth examination of XTLB stock, go to TipRanks’ Overview page.